1717-LSV
15.5.2019 18:55:10 CEST | Business Wire | Press release
Scintomics GmbH and 1717 Life Science Ventures GmbH announced today to have signed an agreement to collaborate in the development of the theranostic pair PentixaFor / PentixaTher.
PentixaPharm GmbH, based in Würzburg, is committed to develop PentixaFor and PentixaTher as a theranostic radiopharmaceutical pair, specifically targeting the CXCR4-receptor expressed in most fast progressing diseases, particularly malignant cancers.
Interviews: “We are delighted that in 1717 LSV we have found a strong partner with an outstanding expertise in the clinical development of precision oncologics. Taking the various recent and successful proof-of-concept studies with PentixaFor and PentixaTher in men into account, this joint venture creates optimal conditions for the effective and swift clinical development of this unrivalled and unique pair of theranostic drugs ”, said Prof. Hans-Jürgen Wester, PhD, Founder of Scintomics and Chair for Pharmaceutical Radiochemistry at the Technical University of Munich (TUM), Germany.
“The introduction of 68 Ga-PentixaFor may be regarded as a milestone for clinical PET imaging of CXCR4 expressing malignancies”, added Dr. Hakim Bouterfa Co-founder of 1717 LSV GmbH and CEO of PentixaPharm. “Now we will focus on the next major step to provide CXCR4-directed endoradiotherapy in prospective clinical trials.”
About PentixaFor / PentixaTher
This theranostic pair specifically targets the CXCR4-CXCR12 axis, which is significantly involved in the interaction and proliferation of hematologic and solid tumors and their protective environment. The Gallium-68 based PET agent PentixaFor has demonstrated advanced imaging not only for several different hematologic indications – including leukaemia, lymphoma, and multiple myeloma – but also for other solid tumors like adrenocortical carcinoma, and small cell lung cancer. In addition, other disease conditions, such as atherosclerosis, myocardial infarction, splenosis and stroke and can be targeted with this tracer. The therapeutic counterpart PentixaTher, labeled with α- or β-emitters, offers new treatment options for individualised medicine in terms of endoradiotherapy.
About Scintomics GmbH
Scintomics, based in Fuerstenfeldbruck/Munich, is a privately held company for innovative-targeted theranostics and corresponding radiopharmaceutical technologies with a strong commitment towards personalized cancer care with an exceptional pipeline of functional diagnostics and radiotherapeutics. Scintomics considers the joint venture partnership with 1717 LSV as another important milestone towards a strong positioning as radiopharmaceutical development specialist.
About 1717 LSV GmbH
1717 LSV, based in Berlin, is a privately held company with expertise in the development of targeted precision radiopharmaceuticals for the targeted diagnosis and treatment of malignant oncological diseases. By enabling novel radiopharmaceutical therapies to traverse early stages of manufacturing and clinical development, 1717 LSV brings innovative drug candidates to patients with unmet medical needs.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190515005776/en/
Contact:
For Scintomics Saskia Kropf General Manager tel. +49 8141 150 550 s.kropf@scintomics.com www.scintomics.com For 1717 LSV Dr. Jens Kaufmann General Manager tel. +49 30 941084-422 jens.kaufmann@1717LSV.com www.1717LSV.com For PentixaPharm Dr. Hakim Bouterfa CEO tel. +49 172 6290822 or +49 931 304998310 hakim.bouterfa@1717LSV.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SWISSto12 Partners With German Consortium HPS/LSS on First-Ever Unfurling Antenna Reflector to Be Built in Europe for Commercial GEO Telecommunications Satellite5.5.2026 09:00:00 CEST | Press release
Latest contract awarded signals strong momentum in SWISSto12’s strategy to strengthen European capabilities to build end-to-end space systems SWISSto12 announced today a major contract with German high-performance space subsystem providersHPS/LSS. The Munich-based consortium will provide a large deployable reflector subsystem (LDRS) for the NEASTAR-1 mission, built on HummingSat, enabling the world’s first direct-to-device media broadcasting capabilities from geostationary orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260505082353/en/ SWISSto12 enables world-first approach to GEO-based D2D connectivity, leveraging an unfurling antenna, in collaboration with HPS/LSS The German-led antenna reflector subsystem is the result of more than 15 years of development under the European Space Agency’s (ESA) Advanced Research in Telecommunications (ARTES) programme, ESA’s Earth Observation Technology Development activities, and
Wolters Kluwer advances Libra legal AI workspace with enhanced contract review and integrated workflows5.5.2026 09:00:00 CEST | Press release
New release introduces more seamless experience for end-to-end legal work Wolters Kluwer Legal & Regulatory today announced a new release of Libra by Wolters Kluwer, its legal AI workspace integrating major workflow capabilities with trusted, expert-generated content. The update introduces significant advancements in contract review, workflow integration and usability, and strengthens Libra’s role as an all-in-one platform where legal professionals can research, draft, review and analyze in a connected and integrated environment. Based on customer feedback, the new release focuses on four key areas: stronger organization across projects, a more powerful and flexible review experience, deeper integration between chat and structured workflows, and a refreshed visual and interaction design. Together, these enhancements respond directly to user feedback and reflect Wolters Kluwer’s focus on user-centric, trusted AI. “With this release, we are making a clear step forward in how legal profes
euroAtlantic Airways Appoints Pauls Calitis as CEO to Lead Next Phase of Growth5.5.2026 09:00:00 CEST | Press release
euroAtlantic Airways (“EAA”), a leading global provider of passenger widebody aircraft wet-leasing and charter services, and Njord Partners portfolio company, is pleased to announce the appointment of Pauls Calitis as Chief Executive Officer, effective 18 May 2026. Pauls will succeed Stewart Higginson, who has served as CEO since early 2024 and who will assume the role of Non-Executive Chairman of the Board. The appointment marks the next phase of the company’s development under Njord Partners. Pauls brings more than three decades of expertise in the aviation industry, most recently serving as Chief Operating Officer and Executive Board Member at airBaltic, having also held the role of Interim Chief Executive Officer in 2025. Over his career progressing from pilot to senior executive leadership, he played a central role in the airline’s development and transformation into one of Europe’s most efficient and respected carriers. His leadership helped establish the airline as a benchmark f
SES’s O3b mPOWER Satellite Network to Connect Seven New Petrobras FPSOs5.5.2026 08:50:00 CEST | Press release
New FPSOs will enter into operation in Brazil between 2026 and 2030 to meet the energy sector’s growing demand SES, a leading space solutions company, will provide service on its high-capacity medium-Earth orbit (MEO) satellite network, O3b mPOWER, to Petrobras, the Brazilian state-owned oil company, to connect multiple new Floating Production, Storage and Offloading systems (FPSOs). The projects will go into operation in the coming years, expanding Petrobras’ oil and gas production capacity to meet national energy needs and contribute to global oil markets. FPSOs are modern and efficient oil production platforms, responsible for processing, collecting, storing, and transferring oil to shuttle tankers, directly from subsea wells in deepwater fields. FPSOs offer the flexibility, capacity, and operational resilience needed to sustain large-scale offshore production in remote and challenging environments. Brazil is home to the majority of the offshore projects under development worldwide,
Regnology Completes Acquisition of Moody’s Regulatory Reporting & Asset and Liability Management (ALM) Solutions5.5.2026 08:00:00 CEST | Press release
Transaction strengthens Regnology’s global position as the go‑to partner for AI‑powered regulatory reporting, risk, and ALM Regnology, a global provider at the intersection of regulatory, risk, finance and supervisory technology, today announced the completion of its acquisition of Moody’s Regulatory Reporting & ALM Solutions business. The transaction expands Regnology’s solution portfolio with Moody’s comprehensive capabilities covering Basel III compliance, IFRS 9 impairment, large‑bank asset and liability management (ALM), Solvency II insurance reporting, and prudential and statistical regulatory reporting. The transaction closes at a pivotal inflection point. Financial institutions face intensifying regulatory scrutiny, growing data complexity, and rising expectations for governance and auditability, while advances in artificial intelligence are creating new opportunities to modernize control frameworks and operating models. Regnology is responding by accelerating its Straight-Thro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom